ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management with improved quality of weight loss and long-term maintenance
Differentiated amylin-based pipeline, including an AMYR3 peptide agonist (ALV-200) and oral small molecule therapies
Company backed by a proven leadership team with deep metabolic disease development and commercialization experience
Series A led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital and other healthcare investors
PHILADELPHIA and COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. ("Alveus"), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced its launch with a $159.8 million Series A financing. Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company's lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.
The Series A was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare investors. In conjunction with the financing, Jan Van den Bossche, Partner of Andera Partners and Claudio Nessi, Managing Director ...